Phil
Phil (PHIL Inc.) sells an integrated digital hub and direct-to-patient platform that helps retail and specialty-lite pharma brands maximize prescription starts, coverage, adherence, and gross-to-net, serving manufacturers as enterprise customers while operating its own 50-state pharmacy network and in-house PHILRx pharmacy for patients.
- Company typePrivate
- Founded2015
- HeadquartersScottsdale, United States
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What Phil does
Phil (PHIL Inc.) is a private, Scottsdale-headquartered pharmaceutical commercialization software company founded in 2015 that sells an integrated medication access platform to pharma manufacturers — primarily retail and specialty-lite brands. The platform combines two complementary modules: PHIL Core, a digital hub that handles prior authorization (including a proprietary "1-click PA" process), benefits verification, and HCP engagement; and PHIL Direct (Direct-to-Patient 2.0), launched in September 2025, which layers brand-controlled intake, telemedicine, flexible coverage/cash/hybrid routing, and eCommerce-style fulfillment on top of the core. Underlying these modules is a 50-state integrated pharmacy network with reported 99%+ plan coverage, an in-house cash pharmacy operated through subsidiary PHILRx, LLC (locations in Scottsdale, AZ and Columbus, OH, NPI 1487163598), a wholesale distribution arm, and an AI-supported data layer surfacing 120+ real-time script-level data points.
The platform is HIPAA- and AICPA SOC-compliant, SMS-based for app-free enrollment, and supports 120+ languages. PHIL serves three distinct user groups: pharma manufacturers (the enterprise paying customer, addressed via a consultative sales-led motion with custom multi-year contracts and a supporting GTN Calculator tool), patients (end users of prescriptions, served free of charge via PHILRx with lifetime free delivery), and healthcare providers (prescribers who e-prescribe through PHILRx via EMR pharmacy directories). Revenue is generated through enterprise partnerships with pharma brands, with programs combining PHIL Core and PHIL Direct in configurable coverage-first, cash-pay, or hybrid models. Pricing is not publicly disclosed; demos are booked on a quote basis.
The company has raised $56M in Series D equity (June 2021, led by Warburg Pincus, with potential up to $100M) and $60M of growth debt from K2 HealthVentures (July 2025) earmarked specifically for AI integration and therapeutic-area expansion. The company has stated it reached cash flow positive status following the 2021 Series D, and reports 150% year-over-year net revenue growth in 2024 alongside 10x prescription volume growth since 2021.
Phil firmographics
Firmographics- Name
- Phil
- Legal name
- PHIL Inc.
- Website
- https://phil.us
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Phil (PHIL Inc.) sells an integrated digital hub and direct-to-patient platform that helps retail and specialty-lite pharma brands maximize prescription starts, coverage, adherence, and gross-to-net, serving manufacturers as enterprise customers while operating its own 50-state pharmacy network and in-house PHILRx pharmacy for patients.
- Ownership category
- akta.pro rank
Phil industry classification
Industry- Product category
- Pharmaceutical Access Software
- NAICS
- Pharmacies and Drug Retailers (456110), Drugs and Druggists' Sundries Merchant Wholesalers (424210)
- SIC
- Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Retail-Drug Stores And Proprietary Stores (5912)
- akta.pro primary industry
- Virtual Pharmacy & Medication Management Integration Platforms (HLALABAL)
- akta.pro secondary industries
- Pharmacy Benefit Management (PBM) & Pharmacy Network Administration (HLAFALAI), Pharmacy-Integrated Virtual Care & ePrescribing (Employer Benefit) (HLALADAH)
Keywords
Where Phil is headquartered
LocationHeadquarters
- HQ city
- Scottsdale
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
Phil business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Infrastructure
Revenue model
- Pharma Manufacturer Subscription/Partnership Programs: PHIL generates revenue through commercial partnerships with pharma manufacturers (retail and specialty-lite brands), providing access programs combining the PHIL Core digital hub and PHIL Direct DTP platform. Programs are customized to each brand's needs with flexible intake, coverage, cash-pay, and hybrid models. Pricing is not publicly disclosed; demos are booked on a consultative basis.
- Growth Debt Financing (Capital Markets): PHIL secured $60 million in growth capital from K2 HealthVentures in July 2025 to accelerate AI integration, supplementing its Series D equity funding of $56 million raised in 2021 (with potential investment up to $100 million from Warburg Pincus). Revenue stream supplemented by growth debt financing.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Quote-based enterprise partnership pricing for pharma manufacturers |
| Other | Pay-as-you-go | Free for patients with active accounts (free delivery, lifetime) |
Go-to-market motion1 record
Distribution channels5 records
Marketing channels9 records
Phil product offering
Product offeringCore offering
PHIL operates a software-driven pharmaceutical commercialization platform that combines a digital hub (PHIL Core) for prior authorization, benefits verification, and patient/HCP engagement with a Direct-to-Patient 2.0 layer (PHIL Direct) for intake, telemedicine, coverage/cash-pay routing, and fulfillment. The platform is delivered to pharma manufacturers as an alternative access channel, supported by a 50-state integrated pharmacy network, an in-house cash pharmacy (PHILRx), a wholesale distribution arm, and AI-powered data and insights. Programs are customized per brand with Coverage-First, Cash-Pay, or Hybrid routing models.
Product overview
PHIL offers a single integrated medication access platform built from two complementary sub-products — PHIL Core (the digital hub that handles prior authorization, benefits verification, and patient/HCP engagement) and PHIL Direct (the Direct-to-Patient 2.0 layer that adds intake, telemedicine, flexible routing, and brand-led eCommerce-style fulfillment) — served by an underlying dispense network, an in-house cash pharmacy (PHILRx, with locations in OH and AZ), a wholesale distribution arm, and an AI-powered data and insights layer. The platform is delivered to pharma manufacturers (especially retail and specialty-lite brands) as an alternative access channel and is configured per brand, with the GTN Calculator available as a supporting tool.
Differentiator
Problem solved
Functional benefit
Brands
- PHILRx: In-house and contracted retail pharmacy service used by patients, providers, and prescribers for affordable prescription fulfillment with free home delivery.
- PHIL Core
- PHIL Direct
Products and services
- PHIL Platform Unified all-in-one medication access platform combining PHIL Core (digital hub) and PHIL Direct (direct-to-patient 2.0), plus integrated pharmacy network, wholesale arm, in-house cash pharmacy, and data & insights layer, designed to maximize starts, coverage, adherence, and commercial performance for retail and specialty-lite pharma brands.
- PHIL Core Technology-driven digital hub delivering a seamless medication access experience, proprietary 1-click prior authorization and benefits verification, and integrated 50-state pharmacy network; includes a Patient Support Team, HCP Engagement Team, and real-time Data & Insights dashboards for pharma manufacturers.
- PHIL Direct Direct-to-Patient 2.0 solution that creates an eCommerce-like patient access journey, integrating brand marketing assets, intake (in-person HCP, telemedicine, Rx transfer), routing (coverage/cash/hybrid), and fulfillment (wholesale arm, in-house cash pharmacy, dispense network) into one configurable program for pharma manufacturers.
- PHILRx PHIL's patient-facing pharmacy service delivering prescription medications via free home delivery with SMS enrollment, benefits verification, prior authorization support, copay assistance, and refill reminders; operates in-house cash pharmacies in Columbus, OH and Scottsdale, AZ and integrates with a 50-state partner network with 99%+ plan coverage.
Quantifiable outcome
- 2x+ patient starts vs. traditional channels
- +11 more outcomes
Companies that use Phil
Customer profileNamed customers5 records
Segments3 records
Ideal customer profiles2 records
Phil technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration3 records
AI capability6 records
Feature7 records
Phil partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core and flagship.
- Digital Medicine Society (DiMe)corePHIL Inc. is a founding partner of the Digital Medicine Society's (DiMe) pre-competitive initiative 'Optimizing Direct-to-Patient (DTP) Strategies for Pharma.' The coalition brings together founding partners across the healthcare ecosystem including Wheel, Welldoc, Ypsomed, and others to co-create a practical blueprint ensuring DTP models operate safely and earn patient trust. The initiative maps the regulatory landscape, develops guidance for self-pay models, and defines metrics for patient access and affordability.
- Tenpoint Therapeutics LtdflagshipTenpoint Therapeutics and PHIL partnered to launch a Direct-to-Patient cash program for YUVEZZI, the first FDA-approved dual-agent prescription eye drop for presbyopia. The program addresses high out-of-pocket costs and access barriers for approximately 128 million Americans and 2 billion people worldwide affected by presbyopia. It offers transparent pricing, home delivery, and dedicated support to address affordability barriers and support long-term patient adherence. This is a featured partnership prominently displayed across PHIL's website.
- Sprout PharmaceuticalsflagshipSprout Pharmaceuticals and PHIL expanded their Affordable Direct-to-Patient Access Program for Addyi (flibanserin), an innovative women's health brand. The partnership delivers affordable access for patients and has been featured prominently in PHIL's announcements. Achieved 5x first fills per patient and 90%+ dispense coverage as a result.
Scale indicators13 records
Recent moves7 records
Expansion highlights6 records
Phil competitors and assessment
Company assessmentDirect peers
- Alto Pharmacy: Tech-enabled retail and specialty-lite mail-order pharmacy offering app-based enrollment, free same-day delivery, PA support, and cash-pay programs, directly overlapping with Phil's PHILRx and DTP 2.0 value proposition for branded retail and specialty-lite therapies.
- Capsule Pharmacy: Consumer-grade digital pharmacy with same-day delivery, in-app PA and benefits support, and a focus on branded retail medications; competes head-to-head with Phil's patient-facing pharmacy and DTP experience.
- Truepill: API-first pharmacy and telehealth infrastructure platform powering DTP cash-pay and brand-led programs for pharma and consumer health companies, comparable to Phil's technology stack and pharma manufacturer DTP offering.
Broad incumbents
- Amazon Pharmacy: Amazon-owned online pharmacy offering home delivery, transparent pricing, and integrated Prime experiences; a dominant incumbent in retail DTP that competes on convenience and scale, increasingly moving into branded specialty and cash-pay programs relevant to Phil's customer base.
- EVERSANA: Large pharma commercialization services platform offering hub services, patient services, PA and access support, and specialty distribution; directly comparable to Phil's hub-and-DTP offering as a broader incumbent serving pharma manufacturers.
- CoverMyMeds (McKesson): McKesson-owned electronic prior authorization, benefits verification, and patient access network widely used across U.S. pharma; overlaps with Phil's 1-click PA workflow and hub services from an established incumbent perspective.
- Optum Specialty Pharmacy (UnitedHealth Group): One of the largest U.S. specialty pharmacy and patient access operations, embedded within UnitedHealth's payer-PBM-provider stack; competes with Phil for branded and specialty-lite brand access, adherence, and hub services at scale.
- Walgreens Specialty Pharmacy: National retail and specialty pharmacy chain with centralized specialty operations, hub services, and home delivery, providing an established incumbent alternative for pharma manufacturers evaluating access partners like Phil.
Emerging players
- Hims & Hers Health: Consumer telehealth and DTP platform for branded and generic therapies with its own pharmacy fulfillment; increasingly relevant as a buyer of pharma brand partnerships and as a competitive consumer DTP channel overlapping with Phil's PHIL Direct 2.0 model.
- Ro: Vertical telehealth and pharmacy platform operating its own DTP and cash-pay programs across multiple therapeutic areas; competes with Phil for branded pharma manufacturer DTP partnerships and consumer-grade patient access experiences.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat7 records
Key risks6 records
Key highlights8 records
Customer concentration
Phil social profiles
Digital presencePhil compliance and trust
Trust signalCompliance2 records
Phil financial estimates
Financial estimateRevenue estimate
Valuation estimate
Phil leadership team
Management profileNumber of profiles
Profiles8 records
Phil subsidiaries and ownership
Company hierarchySubsidiaries1 record
Phil funding detail
Funding detailFunding overview
Funding rounds10 records
Investors15 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Phil M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Phil
What does Phil do?
PHIL operates a software-driven pharmaceutical commercialization platform that combines a digital hub (PHIL Core) for prior authorization, benefits verification, and patient/HCP engagement with a Direct-to-Patient 2.0 layer (PHIL Direct) for intake, telemedicine, coverage/cash-pay routing, and fulfillment. The platform is delivered to pharma manufacturers as an alternative access channel, supported by a 50-state integrated pharmacy network, an in-house cash pharmacy (PHILRx), a wholesale distribution arm, and AI-powered data and insights. Programs are customized per brand with Coverage-First, Cash-Pay, or Hybrid routing models.
Is Phil a public or private company?
Phil is a private company. It is classified as venture growth investor backed and is currently operating.
When was Phil founded?
Phil was founded in 2015. It employs 1 to 10 people.
Where is Phil based?
Phil is headquartered in Scottsdale, United States, in the North America region.
How does Phil make money?
Two revenue lines are on record. Pharma Manufacturer Subscription/Partnership Programs are the primary driver. The others are growth Debt Financing (Capital Markets).
Who are Phil's main competitors?
Direct peers on record are Alto Pharmacy, Capsule Pharmacy and Truepill. Broad incumbents are Amazon Pharmacy, EVERSANA, CoverMyMeds (McKesson), Optum Specialty Pharmacy (UnitedHealth Group) and Walgreens Specialty Pharmacy. Emerging players are Hims & Hers Health and Ro.
Does Phil have an API?
No public API is recorded for Phil.
What industry is Phil in?
Phil's product category is Pharmaceutical Access Software. Its primary akta.pro industry code is HLALABAL, Virtual Pharmacy & Medication Management Integration Platforms, with a secondary code of HLAFALAI, Pharmacy Benefit Management (PBM) & Pharmacy Network Administration. Its NAICS code is 456110 and its SIC code is 5122.